No encontrará nuestro modelo en ningún otro lugar: la estrategia eCOA, una potente plataforma de DCT y un equipo in situ de servicio completo, todo ello bajo un mismo techo virtual.
ObvioGo empowers CROs to scale smarter and move faster with a flexible platform purpose-built for modern hybrid and virtual trials. Developed from deep decentralized trial expertise, ObvioGo simplifies operations, speeds execution, and strengthens data integrity—while giving CROs the oversight they need to stay in control.
Novotech, Asia-Pacific’s largest biotech CRO with more than 3,700 studies, has named ObvioHealth its preferred decentralized trial partner. Together, we deliver virtual and hybrid studies that shorten timelines, reduce costs, and improve patient access—while maintaining high standards in data quality and operational efficiency. With Novotech’s regional expertise and ObvioHealth’s platform, it enables seamless scalability across global markets.
Today’s biotech sponsors demand greater speed, operational flexibility, and broader access to real-world data, driving a strategic shift toward the FSP model. ObvioHealth equips CROs with digital infrastructure to meet these expectations, reduce site burden, enhance engagement, and streamline data workflows. From protocol design to closeout, we help CROs scale global studies—efficiently, compliantly, and without compromise.
“At PRO, we’re seeing DCTs become more complex as participants demand greater flexibility. Our partnership with ObvioHealth reflects our shared commitment to innovation, data quality, and patient-centered design. ObvioGo delivers the tools both HCPs and participants need throughout the trial journey.”
— Susan Dallabrida, CEO, SPRIM PRO
ObvioGo helps CROs launch multi-country trials in parallel—reducing time-to-first-patient by up to 50%. Our no-code builder, standardized workflows, and integrated tools accelerate protocol design, submissions, and site activation.
From ethics approvals to deployment, ObvioGo simplifies global execution with built-in localization, regulatory alignment, and multilingual tools. CROs can expand into new markets faster—with less vendor overhead and fewer site delays.
With mobile-first eConsent, automated reminders, and virtual coordinator access, ObvioGo keeps patients engaged and compliant. CROs benefit from higher retention, richer datasets, and fewer gaps in key endpoints—fueling faster analysis and regulatory readiness.
ObvioGo captures data directly at the source with smart eSource logic, compliance alerts, and AI-powered dashboards. CRO teams reduce SDV time, spend less on monitoring, and close databases faster—with confidence in every data point.
ObvioGo unifies eConsent, ePRO, telehealth, and integrated RTSM—reducing vendor sprawl and simplifying operations. With a multi-study license, CROs gain scalable deployment, predictable pricing, and stronger margins—with less overhead and more control.
.png)
At ObvioHealth, we don’t just deliver technology — we enable your team to lead. Through comprehensive training, collaborative study design, and expert support, we equip your SMEs with the skills and confidence to manage trials independently. As your team builds expertise, we stay by your side with tailored guidance and ongoing support, ensuring success across even the most complex studies.
